Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Novo's oral semaglutide successful in two late-stage T2D studies [Seeking Alpha]

Novo Nordisk A/S (NVO) 
Last novo nordisk a/s earnings: 2/5 01:31 am Check Earnings Report
US:NYSE Investor Relations: novonordisk.com/investors.html
Company Research Source: Seeking Alpha
Novo's oral semaglutide successful in two late-stage T2D studies Novo Nordisk (NYSE: NVO positive results In PIONEER 2 LLY Jardiance PIONEER 4 At week 52, the HbA1C-lowering effect in the oral semaglutide cohort was statistically significantly better than Victoza and control (1.2% vs. 0.9% and 0.2%, respectively) as was weight loss at weeks 26 (4.4 kg vs. 3.1 kg and 0.5 kg, respectively) and 52 (4.3 kg vs. 3.0 kg and 1.0 kg, respectively). Previously reported PIONEER 3 MRK The company filed its U.S. marketing application Show less Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for NVO alerts
Opt-in for
NVO alerts

from News Quantified
Opt-in for
NVO alerts

from News Quantified